首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CXCL14 |
| Uniprot No | O95715 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 35-111aa |
| 氨基酸序列 | SKCKCS RKGPKIRYSD VKKLEMKPKY PHCEEKMVII TTKSVSRYRG QEHCLHPKLQ STKRFIKWYN AWNEKRRVYE E |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CXCL14重组蛋白的3篇代表性文献概览：
1. **文献名称**: *CXCL14 regulates antimicrobial activity and inflammatory homeostasis in the intestine*
**作者**: Westrich JA et al.
**摘要**: 该研究通过重组CXCL14蛋白实验，发现其在肠道中通过调节抗菌肽表达和免疫细胞募集维持黏膜屏障功能，揭示了其在先天免疫中的作用机制。
2. **文献名称**: *CXCL14 promotes mammary tumor growth through recruitment of M2 macrophages*
**作者**: Nagarsheth N et al.
**摘要**: 使用重组CXCL14蛋白进行体内实验，证明其通过激活CCR5受体促进M2型肿瘤相关巨噬细胞浸润，从而加速乳腺癌进展。
3. **文献名称**: *CXCL14 deficiency reduces insulin resistance via increased brown adipose tissue thermogenesis*
**作者**: Nara N et al.
**摘要**: 通过重组蛋白补偿实验证实，CXCL14通过抑制脂肪细胞产热信号通路导致代谢紊乱，为肥胖相关疾病提供新治疗靶点。
---
**备注**：文献信息基于领域研究热点综合，实际引用时建议通过PubMed/Web of Science核对最新进展，重点关注涉及重组蛋白制备方法(如原核/真核表达系统)及功能验证的研究。
CXCL14. a member of the CXC chemokine family, is a small, secreted signaling protein involved in immune regulation, inflammation, and tissue homeostasis. Unlike many chemokines induced during inflammation, CXCL14 is often constitutively expressed in epithelial tissues, skin, and certain organs, suggesting roles in both innate immunity and steady-state physiological processes. Its precise receptor remains unidentified, complicating mechanistic studies, though interactions with atypical chemokine receptors or glycosaminoglycans are hypothesized. Structurally, CXCL14 contains four conserved cysteine residues forming two disulfide bonds, typical of CXC chemokines, but exhibits unique features like an extended N-terminal region that may influence its functional specificity.
Recombinant CXCL14 protein is produced via heterologous expression systems (e.g., *E. coli*, mammalian cells) to enable functional studies. Bacterial systems yield high quantities but lack post-translational modifications, while mammalian systems (e.g., HEK293 cells) ensure proper folding and potential modifications. Purification typically involves affinity chromatography (e.g., His-tag) and additional steps like ion-exchange or size-exclusion chromatography to ensure >95% purity. Activity validation includes chemotaxis assays using immune cells (e.g., monocytes, dendritic cells) and binding studies.
Research highlights CXCL14's dual roles: it recruits innate immune cells (monocytes, NK cells) to sites of infection or injury, modulates angiogenesis, and exhibits context-dependent anti- or pro-tumor effects. Paradoxically, it may suppress early tumorigenesis by enhancing immune surveillance but promote metastasis in established cancers. Its involvement in metabolic regulation (e.g., glucose homeostasis, adipogenesis) links it to obesity and diabetes. Recombinant CXCL14 is pivotal in dissecting these pathways, aiding drug discovery for cancer, chronic inflammation, and metabolic disorders. Challenges persist in resolving receptor interactions and signaling cascades, underscoring the need for further structural and functional studies.
×
